| HOME >> BIOLOGY >> TECHNOLOGY |
Company Selected to Participate in Gastroenterology Panel Discussion
ISELIN, N.J., Dec. 10 /PRNewswire-FirstCall/ -- Pharmos Corporation (Nasdaq: PARS) announced today that Chief Executive Officer Elkan R. Gamzu, Ph.D. will participate in a gastroenterology-focused panel discussion at the 2007 RBC Capital Markets Healthcare Conference taking place December 12 - 13, 2007 at the Westin New York at Times Square in New York, New York. The panel is entitled "Going With Your Gut: New Treatments for GI Disorders," and is scheduled to commence at 8:00 AM Eastern Time on Wednesday, December 12, 2007.
An audio-only webcast and replay of Pharmos' presentation will be available at http://www.wsw.com/webcast/rbc84/panel1 and can be accessed via the Company's website at http://www.pharmoscorp.com.
Pharmos Corporation is a biopharmaceutical company that discovers and
develops novel therapeutics to treat a range of diseases of the nervous
system, including disorders of the brain-gut axis, with a focus on
pain/inflammation and autoimmune disorders. The Company's lead product,
dextofisopam, is being studied in a Phase 2b clinical trial in patients
with irritable bowel syndrome (IBS). Dextofisopam has completed a Phase 2a
IBS study in which it demonstrated a statistically significant effect
compared to placebo on the primary efficacy endpoint of adequate relief
(n=141, p=0.033) and was very well tolerated. A second clinical program
currently in Phase 2a testing is Pharmos' proprietary NanoEmulsion cream
drug delivery system formulated with the NSAID diclofenac, which is being
studied as a treatm
'/>"/>
| SOURCE Pharmos Corporation Copyright©2007 PR Newswire. All rights reserved |